{"disease":{"id":"treatment-in-her2-negative-metastatic-breast-cancer-patients-with-germline-brca-mutation","name":"treatment in her2 negative metastatic breast cancer patients with germline brca mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04296370","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}